Taysha Gene Therapies, Inc.

NASDAQ:TSHA

Biotechnology

Healthcare
$3.77 +1.53%

+$0.10 today

Market cap
$1.22B
Beta
1.18
P/E (TTM)
-17.7
EPS (TTM)
-$0.35
52W Low $2.25High $7.30

Volume 2.17M

Average 2.73M

Returns on capital

Taysha Gene Therapies, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-44.1%

avg -2455.1%

ROIC

-34.9%

avg 65.2%

ROA

-31.7%

avg -1116.4%

Analysis

ROA is currently the strongest return metric at -31.7% versus its period average of -1116.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Sean Nolan

Chief Executive Officer & ChairmanUSD 1.19M58——

Sukumar Nagendran

President, Head of Research & Development and DirectorUSD 1.04M59936.41K0.33%

Kamran Alam

Chief Financial Officer & Corporate SecretaryUSD 741.9K481.44M0.50%

Berge Minassian

Chief Medical Advisor of UT Southwestern Gene Therapy Program————

Hayleigh Collins

Director of Corporate Communications & Investor Relations————

Frederick Porter

Chief of Staff & Technical Operations Officer————

Michael Johannesen

Chief Legal Officer & Corporate Secretary—60——

Sean McAuliffe

Chief Business Officer————

Emily McGinnis

Chief Patient & External Affairs Officer————

Steven Gray

Chief Scientific Advisor of UT Southwestern Gene Therapy Program————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 10, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

12

$6.66M

Net Transaction Value

−$6.66M

Net selling

Most Active

Nagendran Sukumar

7 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Jul 10, 26

Nagendran Sukumar

Direct

Sell$1.2M
Apr 10, 26

Nagendran Sukumar

Direct

Sell$892K
Feb 4, 26

Alam Kamran

Direct

Sell$7.5K
Jan 26, 26

Nolan Sean P.

Direct

Sell$190.4K
Jan 26, 26

Nagendran Sukumar

Direct

Sell$124.1K
Jan 26, 26

Alam Kamran

Direct

Sell$109.9K
Jan 23, 26

Nolan Sean P.

Direct

Sell$649.7K
Jan 23, 26

Nagendran Sukumar

Direct

Sell$423.4K
Jan 23, 26

Alam Kamran

Direct

Sell$375.1K
Jan 12, 26

Nagendran Sukumar

Direct

Sell$942K

1–10 of 12

Summary

Insiders reported 0 buys worth $0.00 and 12 sells worth $6.66M over the last 12 months. That adds up to net selling of $6.66M. Nagendran Sukumar was the most active insider with 7 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/A+57.5%
+154.3% (5yr)3 analysts
Net IncomeN/AN/AN/A
N/A3 analysts
EBITN/AN/AN/A
N/A3 analysts

Analysis

Recent growth has been strongest in Revenue at +57.5% over three years. Forward estimates point to Revenue at +154.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Taysha Gene Therapies, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about TSHA's management, answered from reported figures.

Who manages TSHA?

Taysha Gene Therapies, Inc. (TSHA) lists 10 active executives. The top listed executive is Berge Minassian, Chief Medical Advisor of UT Southwestern Gene Therapy Program.

Are TSHA insiders buying or selling?

Recent insider activity shows net buying of $53.40M.